Androgen Therapy in Lower-Risk Myelodysplastic Syndrome Can Result in Hematologic Improvement
Patients who received androgen therapy demonstrated improvements in erythroid, platelet, and neutrophil measures.
Patients who received androgen therapy demonstrated improvements in erythroid, platelet, and neutrophil measures.
An assessment of a population of patients with CML revealed that some are not receiving guideline-based treatment, including TKIs.
Although statistically insignificant, results of a randomized study determined the potential for nurse-led interventions as adjunct posttreatment care for lymphoma survivors.
Antibiotic treatment with carbapenem for S. aureus infection was efficacious in patients with cutaneous T-cell lymphomas.
Inferior survival for patients with chronic lymphocytic leukemia who progress with lymphadenopathy.
The rate of 5-year overall survival in patients with myelodysplastic syndrome who underwent second allogeneic hematopoietic stem cell transplantation was 25.3%.
The increased risk for infection seen in pediatric patients receiving transplants from unrelated donors could be a result of intensified graft-versus-host disease prophylaxis.
Though the primary survival endpoints were not met in this study, younger patients experienced improved outcomes with ibrutinib.
Propensity score analysis showed that patients in the inotuzumab ozogamicin arm experienced significantly longer event-free and overall survival.
Patients who experienced reactivation of Epstein-Barr virus also experienced inferior relapse-free survival and increased incidence of relapse.